Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies.

Abstract excerpt

The tumor suppressor p53, often referred to as the “guardian of the genome,” is mutated in more than half of human cancers. These mutations have a significant impact on cancer biology and response to therapy. p53 mutations involve a range of changes that interfere with DNA binding, eliminate tumor suppressor functions, and, in many cases, confer dominant-negative or gain-of-function characteristics that actively...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Therapy
• Share to Molecular Targeted Therapy